Insight Molecular Diagnostics Partners with Quest Diagnostics for GraftAssureCore™ Test Collection

summarizeSummary

Insight Molecular Diagnostics Inc. entered into a strategic Specimen Collection Agreement with Quest Diagnostics Incorporated to facilitate the commercialization of its GraftAssureCore™ test.

check_boxKey Events

• Strategic Specimen Collection Agreement

  Insight Molecular Diagnostics Inc. entered into an agreement with Quest Diagnostics Incorporated on February 20, 2026, for specimen collection services related to its GraftAssureCore™ test.

• Enabling GraftAssureCore™ Commercialization

  This partnership provides access to Quest Diagnostics' extensive collection network, which is crucial for the rollout and adoption of the GraftAssureCore™ blood test, designed to measure donor-derived cell-free DNA.

• Potential for Expanded Technology Rights

  The agreement also includes a commitment for both parties to negotiate additional rights to the GraftAssure technology, suggesting potential for broader future collaboration and market penetration.

auto_awesomeAnalysis

Insight Molecular Diagnostics has secured a crucial partnership with Quest Diagnostics, a leading diagnostic information services provider. This agreement for specimen collection services is a significant step towards the commercialization and broader adoption of the company's GraftAssureCore™ test. For a life sciences company, establishing such a partnership with a major player like Quest Diagnostics de-risks the operational rollout of a new diagnostic product. The commitment to negotiate additional rights to the GraftAssure technology also signals potential for deeper, long-term collaboration, which could further enhance the product's market reach and value. This strategic move follows the company's recent successful $26 million registered direct offering, providing the necessary capital to support such commercialization efforts.